痛风研究中预防发作结局的报告方式:随机对照试验的系统综述与内容分析
该系统综述纳入2008至2018年间的38篇随机对照试验文章,分析痛风发作预防结局的测量与报告方法。研究发现抗炎预防研究多用多种方法报告发作结局,而降尿酸/其他长期治疗研究多采用单一方法,各试验在发作定义、数据采集和报告方法上存在显著异质性。
要点
- 抗炎预防研究平均每篇文章使用4.3种方法报告痛风发作结局
- 降尿酸/其他长期治疗研究最常用报告至少一次发作的患者比例
- 各试验在痛风发作定义、数据采集方法和报告时间段上存在显著异质性
核心结论
- 长期随机对照试验中测量和报告痛风发作预防结局的方法存在广泛差异,凸显了标准化方法的必要性。
研究设计与样本
- 系统检索电子数据库,纳入2008至2018年间报告干预措施对痛风患者发作预防影响的随机对照试验或随机对照试验数据分析文章,共38篇。
- 使用改良Jadad量表评估研究质量,分别提取和综合抗炎预防研究与降尿酸/其他长期治疗研究中测量和报告痛风发作结局的方法。
主要发现
- 共纳入38篇文章,其中10篇报告抗炎预防结局,28篇报告降尿酸/其他长期治疗结局。
- 所有文章总体质量评分良好。
- 各试验在痛风发作定义、数据采集方法、报告方法和报告时间段上存在显著异质性。
- 抗炎预防研究使用多种方法报告痛风发作结局(平均(SD)4.3(2.5)种方法/文章),而降尿酸/其他长期治疗研究多数使用单一方法报告。
- 抗炎预防研究中最常见的报告方法是每例患者痛风发作的平均次数(9篇文章),降尿酸/其他长期治疗研究中最常见的是至少一次痛风发作的患者比例(22篇文章)。
关键数值与推荐
- 抗炎预防研究平均每篇文章使用4.3(SD 2.5)种方法报告痛风发作结局。
- 抗炎预防研究中最常见报告方法为每例患者痛风发作平均次数(n=9篇文章)。
- 降尿酸/其他长期治疗研究中最常见报告方法为至少一次痛风发作的患者比例(n=22篇文章)。
临床怎么用
- 临床解读痛风发作预防试验结果时需注意发作定义和报告方法的异质性,避免直接比较不同报告方式下的发作率。
- 关注抗炎预防研究与降尿酸治疗研究在发作结局报告方法上的差异,结合具体报告指标理解干预效果。
局限性
- 仅纳入2008至2018年间发表的随机对照试验及其数据分析文章,未涵盖其他研究设计或更近期文献。
- 研究聚焦于痛风发作预防结局的报告方法,未评估不同报告方法对结果解释的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: There are many potential ways that gout flares could be reported in clinical trials. The aim of this study was to describe the methods used to measure and report gout flare prevention outcomes in randomized controlled trials (RCTs). METHODS: A systematic search of electronic databases was conducted. Articles published between 2008 and 2018 were included if they were RCTs or articles reporting on analyses of RCT data (i.e. open label extension studies) and reported the impact of an intervention on the prevention of flares in people with gout. The modified-Jadad scale was used to assess study quality. Methods used to measure and report gout flare outcomes were extracted and synthesised separately for studies of anti-inflammatory prophylaxis and urate lowering/other long term therapy. RESULTS: A total of 38 articles were included, with 10 reporting outcomes for anti-inflammatory prophylaxis and 28 for urate lowering/other long term therapies. The overall quality score of all articles was good. There was marked heterogeneity across trials in gout flare definitions, data capture methods, reporting methods and time periods used to report flares. Anti-inflammatory prophylaxis studies used multiple methods to report gout flare outcomes (mean (SD) 4.3 (2.5) methods/article), while the majority of urate lowering/other long term therapy studies used a single method to report gout flare outcomes. The most common reporting method in anti-inflammatory prophylaxis studies was the mean number of gout flares per patient (n = =9 articles), and in urate lowering/other long term therapy studies was the proportion of patients with at least one gout flare (n = =22 articles). Only studies of anti-inflammatory prophylaxis therapy reported flare duration or pain during flare. CONCLUSION: There is wide variation in methods used to measure and report gout flare prevention outcomes in long-term RCTs. These findings highlight the need for standardized methods for studies in which gout flare prevention is an outcome of interest.
引用
- Stewart S, Tallon A, Taylor WJ, et al. How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials. Semin Arthritis Rheum. 2019. PMID: 31796212. doi:10.1016/j.semarthrit.2019.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。